mRNA vaccines scope expands beyond COVID-19
While SARS-CoV-2 vaccines have been capturing the limelight, there has also been progress in other vaccines relevant to travel medicine
The remarkable and rapid progress on development of SARS-CoV-2 vaccines has understandably dominated discussions of vaccine development over the past two years.
Even as the WHO declared COVID-19 a pandemic on 11 March 2020, there were more than 35 biotechnology and academic groups around the world working on vaccine candidates.
The range of vaccine technologies was wide, including live-attenuated, inactivated, DNA, messenger RNA, viral-vector and spike-protein-based vaccines.1
Since then, public attention in Australia has predominantly focused on viral-vector (such as the AstraZeneca vaccine) and messenger RNA vaccines (such as the Pfizer-BioNTech vaccine).
